What is Quris Technologies?
Founded in 2020 and headquartered in Tel-Aviv, Israel, Quris Technologies is at the forefront of pharmaceutical innovation with its Bio-AI Clinical Prediction Platform. This advanced system is designed to significantly improve the accuracy of predicting which drug candidates will be safe and effective in human trials, aiming to reduce the costly and time-consuming failures in traditional drug development pipelines. The company's focus on AI-driven predictive analytics positions it as a key player in the evolving landscape of precision medicine and drug discovery.
How much funding has Quris Technologies raised?
Quris Technologies has raised a total of $9M across 1 funding round:
Angel/Seed
$9M
Angel/Seed (2022): $9M with participation from Softbank Vision Fund, Richter Group, iAngels, Welltech Ventures, and Glenrock Capital
Key Investors in Quris Technologies
Softbank Vision Fund
SoftBank Vision Fund is a global investment fund that supports founders in building market-leading companies through its extensive ecosystem and capital resources, with a particular focus on the transformative power of AI.
iAngels
iAngels is a venture capital firm and investment platform offering accredited investors worldwide exclusive access to curated tech startup and scaleup investment opportunities originating in Israel.
Welltech Ventures
WellTech Ventures is a leading wellness-focused venture capital fund that invests in visionary entrepreneurs reimagining health and wellness technology, aiming to help people live longer, happier, and healthier lives.
What's next for Quris Technologies?
The substantial enterprise-level funding Quris Technologies has garnered, including the recent strategic investment, signals a strong validation of its technology and market potential. This capital infusion is expected to accelerate the company's research and development efforts, expand its platform's capabilities, and potentially facilitate strategic partnerships within the pharmaceutical and biotech industries. Quris Technologies is poised to leverage this backing to further refine its Bio-AI Clinical Prediction Platform, aiming to bring safer and more effective treatments to market faster.
See full Quris Technologies company page
